Tongkat Ali (Eurycoma longifolia)
Tongkat Ali is a Malaysian root whose quassinoids displace testosterone from SHBG and dampen cortisol. The Tambi 2012 Andrologia RCT (n=76, 200 mg/day Physta, 1 month) normalized serum T in 90.8% of hypogonadal men. Effects are largest in low-T, high-stress, over-40 populations and muted in healthy young men.
Tongkat Ali (Eurycoma longifolia) scored 6.6 / 10 (👍 Worth trying) on the BioHarmony scale as a Substance → Adaptogen / Herbal → Adaptogenic Herb.
What It Is
Tongkat Ali (Eurycoma longifolia Jack) is a Malaysian and Indonesian root traditionally brewed as a bitter decoction for energy, libido, and post-partum recovery. Modern standardized hot-water extracts (Physta, LJ100) concentrate quassinoids (primarily eurycomanone), glycosaponins, and bioactive peptides that work through three linked mechanisms: quassinoids competitively displace testosterone from sex-hormone-binding globulin (SHBG), raising free testosterone without new synthesis; eurycomanone also stimulates luteinizing hormone pulsatility in men with depressed HPG signaling, recruiting Leydig cell production; and glycosaponins dampen HPA-axis cortisol output. This is why effects are largest in stressed or hypogonadal men and muted in healthy eugonadal young adults.
Type: Botanical adaptogen (Eurycoma longifolia standardized root extract).
Current status: Not FDA-approved. Sold in the US as an OTC dietary supplement. The EFSA 2021 novel food opinion on Physta concluded "safety not established under any condition of use" citing positive in-vitro clastogenicity and in-vivo DNA damage signals in rat stomach/duodenum at 2,000 mg/kg bw; pregnant and lactating women are explicitly excluded. Standardized extract trade names Physta (Biotropics Malaysia) and LJ100 (HP Ingredients) dominate the clinical literature. Centuries of traditional use across Malaysia, Indonesia, and Vietnam.
Terminology
- LH: Luteinizing hormone, a pituitary gonadotropin that signals Leydig cells in the testes to synthesize testosterone. Eurycomanone supports LH pulsatility upstream of testosterone output.
- FSH: Follicle-stimulating hormone, the paired gonadotropin to LH, drives Sertoli cell support of spermatogenesis. Henkel 2014 showed FSH modulation alongside testosterone improvements.
- SHBG: Sex hormone-binding globulin, a liver-synthesized glycoprotein that binds circulating testosterone in a biologically inactive bound form. High SHBG is common in aging men, endurance athletes, and chronically stressed individuals. Tongkat Ali's primary mechanism is SHBG-displacement of testosterone.
- Eurycomanone: Primary quassinoid in Eurycoma longifolia, the marker compound for Physta standardization (0.8–1.5%) and the active that drives the SHBG-displacement and LH-stimulation mechanisms.
- Quassinoid: A class of bitter, highly oxygenated triterpenoid lactones found in Simaroubaceae plants. Eurycomanone, 13α-21-dihydroeurycomanone, and eurycomalactone are the relevant Tongkat Ali quassinoids.
- Glycosaponin: Saponin glycosides (including eurycomaoside) that contribute to the HPA-axis cortisol-dampening effect. Physta is standardized to ≥40% glycosaponin content.
- POMS: Profile of Mood States, a validated psychometric instrument. Talbott 2013 used it to document improvements in tension, anger, confusion, and vigor subscales.
- T:C ratio: Testosterone-to-cortisol ratio, the principal anabolic-to-catabolic marker in sports endocrinology. Talbott 2013 reported +37% T:C in moderately stressed subjects.
- NOAEL: No-Observed-Adverse-Effect Level. EFSA 2021 could not establish a NOAEL for Physta due to in-vivo DNA damage signals at 2,000 mg/kg bw in rat stomach/duodenum.
- DILI: Drug-Induced Liver Injury. Two Tongkat Ali DILI case reports in the literature, both confounded by heavy anabolic steroid co-use.
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
View 2 routes and 5 protocols
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Oral (Capsule) | 100–300 mg/day standardized hot-water root extract (Physta or LJ100) | 200–600 mg/day (Huberman-era community range) | |
| Oral Root Powder | 1–5 g/day (traditional Malaysian decoction) |
Protocols
Clinical hypogonadal protocol (Tambi 2012) Clinical
- Dose
- 200 mg/day Physta standardized extract
- Frequency
- daily, single AM dose
- Duration
- 4 weeks minimum; retest free T, total T, SHBG at week 4
Only RCT-validated hypogonadal protocol. Normalized serum T in 90.8% of subjects in Tambi 2012.
Stress/cortisol protocol (Talbott 2013) Clinical
- Dose
- 200 mg/day Physta standardized extract
- Frequency
- daily, single AM dose
- Duration
- 4 weeks
Primary endpoint was cortisol modulation and mood in moderately stressed (non-hypogonadal) adults.
Huberman-era community protocol Anecdotal
- Dose
- 400 mg/day Physta or LJ100
- Frequency
- daily, single AM dose
- Duration
- 8–12 weeks on, then cycle off
Popularized by the Huberman Tongkat + Fadogia Agrestis T&T stack. Not clinically validated at this dose. Evidence base is the 200 mg RCTs extrapolated upward.
Cycled community protocol Anecdotal
- Dose
- 200–400 mg/day
- Frequency
- 5 days on, 2 days off OR 8 weeks on, 2 weeks off
- Duration
- indefinite
No clinical evidence that cycling matters given lack of tolerance signal. Cycling is a hedge against unknown long-term effects, not optimization.
Acute stress / travel use Anecdotal
- Dose
- 200 mg AM
- Frequency
- daily
- Duration
- 7–14 days
Short-window use for travel, deadline, or competition. Targets cortisol modulation and mood, not hormonal rebuild.
How this score is calculated →
Upside (1.83 / 5.00)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 3.0 | 0.750 | |
| Breadth of Benefits | 15% | 3.0 | 0.450 | |
| Evidence Quality | 25% | 3.0 | 0.750 | |
| Speed of Onset | 10% | 2.8 | 0.280 | |
| Durability | 10% | 1.8 | 0.180 | |
| Bioindividuality Upside | 15% | 2.8 | 0.420 | |
| Total | 2.830 |
Upside Rationale
Efficacy (3.0/5.0). Moderate, population-dependent. The Leitão 2021 Phytother Res meta-analysis (11 RCTs, n=530) found a statistically significant total T increase with standardized extract vs placebo; pooled effect size Cohen's d approximately 0.4–0.6. Effect sizes are largest in men with confirmed low baseline T: Tambi 2012 (Andrologia) reported 90.8% of hypogonadal men (n=76, 200 mg/day Physta, 1 month) normalized into the 350–1,000 ng/dL reference range, with mean total T rising from 411 to 742 ng/dL. Talbott 2013 (JISSN) in moderately stressed subjects (n=63, 200 mg/day Physta, 4 weeks) showed salivary cortisol −16%, T:C ratio +37%, and POMS improvements across tension, anger, and confusion. Hamzah 2003 (5-week RCT, 100 mg/day, n=14 trained men) reported +1.8 kg lean mass and +5.6% to +6.1% strength gains vs control. In healthy eugonadal young men the signal is noticeably weaker, so the score reflects the delta-to-baseline pattern rather than a flat population effect.
Breadth of Benefits (3.0/5.0). Three systems move together rather than one hero effect. Hormonal (free T, LH, mild E2 via aromatization), stress (cortisol, HPA dampening via glycosaponins), and mood/performance (POMS scores, grip strength, libido in George 2014 Physta RCT and Henkel 2014 supplementation trial). Muscle and strength outcomes are present but smaller than creatine or resistance training. Sleep, fertility parameters, and bone are touched in some trials but not robustly. This is a multi-axis modulator, not a systemic healthspan lever.
Evidence Quality (3.0/5.0). Base tier is high: meta-analysis of 11 RCTs, multiple independent replications for stress and hypogonadism endpoints, and centuries of traditional use across Malaysia, Indonesia, and Vietnam. Significant integrity adjustments apply: Biotropics Malaysia (Physta owner) funded or co-authored the majority of pivotal trials (Tambi, Talbott, George, Henkel), and independent non-industry replication is sparse, so a v0.5 −0.4 industry-funding penalty applies. No Cochrane review exists. Most trials are small (n=30–100) and short (4–12 weeks). Mechanistic data (SHBG displacement, LH stimulation, HPA dampening) is well-characterized. Net: solid moderate evidence, not transformative.
Speed of Onset (2.8/5.0). Stress and mood endpoints shift inside 2–4 weeks (Talbott 2013). Free testosterone rises over 2–4 weeks in responders. Total T normalization in hypogonadal men was documented at the 1-month mark in Tambi 2012. Libido and subjective energy effects are often reported in week 1 anecdotally. Not immediate like caffeine; not slow like NAD precursors.
Durability (1.8/5.0). This is the weak dimension. The mechanism is functional, not structural: as long as quassinoids occupy SHBG and glycosaponins modulate HPA tone, free T and cortisol move favorably. Stop the extract and the hormonal delta reverts over 1–3 weeks in most trials that included washout. There is no evidence of permanent HPG recalibration. You are renting the effect, not buying an adaptation.
Bioindividuality Upside (2.8/5.0). Responder profile is narrower than the marketing implies. Strong responders: men over 40 with age-related T decline, chronically stressed men with elevated cortisol, men with measured low free T or high SHBG, and men recovering from overtraining or caloric deficit. Weak responders: healthy eugonadal men under 30, men with already-optimal free T, and women (most trials excluded them). Roughly 40–50% of the biohacker audience gets a meaningful signal. The remainder feel little to nothing beyond a subtle libido nudge.
Downside (0.96 / 5.00)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety Risk | 30% | 2.2 | 0.660 | |
| Side Effect Profile | 15% | 2.5 | 0.375 | |
| Financial Cost | 5% | 1.8 | 0.090 | |
| Time/Effort Burden | 5% | 1.2 | 0.060 | |
| Opportunity Cost | 5% | 1.5 | 0.075 | |
| Dependency / Withdrawal | 15% | 1.0 | 0.150 | |
| Reversibility | 25% | 1.2 | 0.300 | |
| Total | 1.710 | |||
| Harm subtotal × 1.4 | 2.079 | |||
| Opportunity subtotal × 1.0 | 0.225 | |||
| Combined downside | 2.304 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 0.964 |
Downside Rationale
Safety Risk (2.2/5.0). Standardized extract trials (Physta, LJ100) report clean safety profiles comparable to placebo across 4–12 week durations, including no clinically significant changes in liver enzymes, kidney markers, or lipid panels. Two published DILI case reports exist in bodybuilders: a 47-year-old male with bilirubin 7.5, ALT 470, AST 234, and a 2025 ACG case, both confounded by heavy anabolic steroid co-use. LiverTox classifies the likelihood as category D (rare cause of clinically apparent liver injury). The EFSA 2021 novel food opinion flagged positive in-vitro clastogenicity and in-vivo DNA damage in rat stomach and duodenum at 2,000 mg/kg body weight, roughly 160–200× the human clinical dose but not dismissable. Catastrophic risk screen: NEGATIVE for the verified extract (no intrinsic life-threatening AEs at clinical doses). Per v0.5 Score-the-Compound rules, heavy-metal contamination and eurycomanone-void adulteration of cheap bulk supply are extrinsic supply-chain issues and do NOT inflate this dimension - they belong in the Verdict and Supply Chain Warning. Score reflects only the intrinsic EFSA DNA-damage flag and the two confounded DILI reports.
Side Effect Profile (2.5/5.0). Reported in trials and community: insomnia when dosed in the evening, irritability and what the community calls "Tongkat rage" during weeks 1–2 as androgenic tone rises, libido surges that some users find disruptive, mild GI upset, and occasional headaches. Most subside within 2 weeks or resolve with AM-only dosing. Estradiol can rise modestly via aromatization of new free T, which is rarely symptomatic but matters for men predisposed to gynecomastia or water retention.
Financial Cost (1.8/5.0). Standardized Physta or LJ100 extracts run roughly $20–40/month at 200–400 mg/day. Per v0.5 accessible-channel rules, scored at the verified-extract price, not the cheap bulk price (bulk is not the accessible channel we endorse). Not covered by insurance. Inexpensive relative to most hormonal support protocols.
Time/Effort Burden (1.2/5.0). 200 to 400 mg once in the morning per the Tambi 2012 Physta protocol, roughly five seconds to swallow and under ten seconds of total daily friction. Food co-ingestion is optional since eurycomanone bioavailability is not significantly food-dependent per Abdullah 2021 pharmacokinetic data. Community cycling conventions (4 to 8 weeks on, 1 to 2 weeks off) are lore-driven rather than RCT-supported, though LH and SHBG axis considerations give them a theoretical basis. Never dose in the evening; the insomnia signal is consistent across community reports. Ashwagandha at twice daily is more effort; rhodiola sits at parity.
Opportunity Cost (1.5/5.0). Stacks cleanly with creatine, zinc, boron, ashwagandha, and most stress or sleep protocols. Competes mildly with ashwagandha for the cortisol-modulator slot since both dampen HPA output. Not a substitute for TRT, sleep, resistance training, or fat loss in men with lifestyle-driven low T.
Dependency/Withdrawal (1.0/5.0). No documented adaptation, tolerance, or HPG-axis downregulation from standardized doses. Free T returns to baseline on cessation but there is no rebound hypogonadism. Per v0.5 dependency-vs-addiction framework, this is the substrate-class floor: no withdrawal, no craving, no rebound.
Reversibility (1.2/5.0). Eurycomanone plasma half-life is roughly 5 to 8 hours per Abdullah 2021, with total plasma clearance inside 24 to 48 hours of the last dose. Testosterone returns to pre-supplementation baseline within 1 to 3 weeks of cessation per Tambi 2012 follow-up data, with no documented permanent HPG axis recalibration in any published trial, no receptor downregulation, and transient cortisol modulation per Talbott 2013. Contrast this with anabolic steroid use, where exogenous androgens can drive permanent HPG suppression. Tongkat Ali is modulatory rather than suppressive, and the reversibility profile looks nothing like exogenous androgen therapy.
Verdict
✅ Best for: Men over 35 with measured low or borderline free testosterone, high SHBG, or elevated cortisol. Stressed men in demanding training blocks or caloric deficits who want to preserve androgenic tone without TRT. Frequent travelers or executives using it situationally as a stress buffer. Men who have already optimized sleep, training, and nutrition and want a mild, reversible hormonal nudge. Use Physta or LJ100 only, 200 mg/day clinical or 400 mg/day community dose, AM only, 8–12 week cycles.
❌ Avoid if: You are pregnant or nursing (EFSA explicit exclusion). You have a hormone-sensitive cancer (prostate, breast) or a strong family history of one. You are on TRT without estradiol monitoring (additional free T on top of exogenous T without an aromatase-inhibitor plan can drive E2 into symptomatic range). You are on immunosuppressants (preliminary immune activation signal). You are a healthy eugonadal young man expecting dramatic effects; the signal will likely disappoint. Critically, avoid any product that is not a verified Physta or LJ100 standardized extract. Malaysian market surveys found 42% of commercial Tongkat Ali products contained zero measurable eurycomanone, and 26–36% exceeded the 0.5 ppm mercury limit, with individual samples reaching 2.35–5.30 ppm (4–10× the limit). Bulk Southeast Asian root powder, Amazon no-name brands, and unverified "male enhancement" products (some adulterated with sildenafil analogs) are functionally lottery tickets for mercury exposure with no active ingredient. This is a supply-chain warning, not a knock against the compound itself.
Use Case Breakdown
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
| Use Case | Score | Summary |
|---|---|---|
| 👍 Hormonal / Endocrine | 6.5 | Leitão 2021 meta-analysis (11 RCTs, n=530) found statistically significant total T increase. Largest effects in hypogonadal and over-40 men. |
| 👍 Stress / Resilience | 6.5 | Talbott 2013 (n=63 moderately stressed): salivary cortisol −16%, T:C ratio +37%, POMS improvements across tension/anger/confusion. |
| 👍 Libido / Sexual Health | 6.3 | George 2014 Physta RCT and anecdotal signal converge. Effects inside 2 weeks via free T liberation and cortisol dampening. |
| 👍 Energy / Fatigue | 6.0 | Subjective reports strong in forums; mechanistic via T:C ratio restoration. No direct fatigue RCTs. |
| 👍 Mood / Emotional Regulation | 6.0 | POMS tension, anger, confusion improvements in Talbott 2013. Downstream of T:C ratio restoration. |
| 👍 Geriatric / Aging Population | 6.0 | Age-related free T decline is the strongest responder profile. Henkel 2014 in physically active seniors showed T and muscle strength gains. |
| 👍 Strength / Power | 5.8 | Hamzah 2003 (n=14, 100 mg/day, 5 weeks): +1.8 kg lean mass, +5.6% bench, +6.1% leg press. Smaller than creatine. |
| ⚖️ Muscle Growth / Hypertrophy | 5.5 | Lean mass gain in Hamzah 2003 is modest. Mechanism via androgenic signaling. No long-duration hypertrophy RCTs. |
| ⚖️ Recovery / Repair | 5.5 | Cortisol and T:C data support it for overreached athletes. No direct recovery-endpoint RCT. |
| ⚖️ Fertility (Male) | 5.3 | Tambi 2010 and Ismail 2012 report sperm parameter improvements; evidence is open-label or small n. Henkel 2014 showed semen volume, motility, concentration improvements. |
| ⚖️ Body Composition / Fat Loss | 5.2 | Small lean mass gain in Hamzah. Fat loss signal is weak and indirect via androgenic tone. |
| ⚖️ Sleep Quality | 4.8 | Indirect via cortisol. Evening dosing actively disrupts sleep - AM-only mandatory. |
| ⚖️ Endurance / Cardio | 4.8 | Limited direct endurance data. Mechanism via T:C ratio in overreached athletes. |
| ○ Anxiety | 4.5 | Stress-axis modulation plausible. No direct anxiety-specific RCTs. |
| ○ Sleep Architecture (Deep/REM) | 4.5 | No direct sleep architecture data. |
| ○ Circadian Rhythm / Chronobiology | 4.5 | No direct evidence; AM-only dosing preserves cortisol rhythm. |
| ○ VO2 Max | 4.5 | No direct VO2 data. |
| ○ Reaction Time / Coordination | 4.5 | No direct evidence. |
| ○ HRV / Vagal Tone / Autonomic Balance | 4.5 | Indirect via cortisol/HPA dampening; no direct HRV RCT. |
| ○ Healthspan | 4.5 | Indirect via T:C ratio and androgenic tone in older men. No direct healthspan RCTs. |
| ○ Bone / Joint Health | 4.5 | Mechanistic plausibility via free T (testosterone is osteogenic). No dedicated bone RCT. LongJax marketing is positioning, not a distinct extract. |
| ○ Depression | 4.0 | POMS depression subscale improvement in Talbott but not a primary endpoint. No depression-specific RCT. |
| ○ Flexibility / Mobility | 4.0 | No direct evidence. |
| ○ Immune Function | 4.0 | Preliminary in-vitro immune activation signal. Not a primary indication. Caution in immunosuppressed users. |
| ○ Injury Recovery | 4.0 | Indirect via T:C ratio in overreached/injured athletes. No dedicated injury-recovery RCT. |
| ○ Metabolic Health | 3.8 | Indirect via free T in older men. No direct metabolic endpoints. |
| ○ Anti-Inflammatory | 3.8 | Cortisol reduction is anti-inflammatory-adjacent. No direct CRP/IL-6 RCT. |
| ○ Kidney Function | 3.8 | Standardized extract trials show no clinically significant kidney marker changes. |
| ○ Cognition / Focus | 3.5 | Mood improvement may lift perceived focus. No direct cognitive RCTs. |
| ○ Memory | 3.5 | No direct memory RCT data. |
| ○ Flow State / Peak Mental Performance | 3.5 | Indirect via mood and arousal; no direct evidence. |
| ○ Blood Sugar / Glycemic Control | 3.5 | No direct glycemic RCT data. |
| ○ Antioxidant / Oxidative Stress | 3.5 | In-vitro antioxidant activity. No human oxidative-stress biomarker RCTs. |
| ○ Mitochondrial | 3.5 | Indirect via T:C and muscle strength. No direct mitochondrial endpoints. |
| ○ Cardiovascular | 3.2 | Neutral lipid data in RCTs. No meaningful CV endpoint evidence. Estradiol may rise via aromatization of new free T. |
| ○ Hair / Nail Health | 3.2 | Androgenic mechanism is a two-edged sword: may worsen AGA in DHT-sensitive men while supporting body hair. |
| ○ Fertility (Female) | 3.0 | Most trials excluded women; EFSA 2021 excludes pregnant/lactating. Perimenopausal pilot data (Tambi 2011 conference abstract, not peer-reviewed) is not robust. |
| ○ Neuroplasticity | 3.0 | No direct evidence. |
| ○ Creativity / Divergent Thinking | 3.0 | No direct evidence. |
| ○ Longevity / Lifespan | 3.0 | No longevity endpoint data; mechanism is functional, not structural. |
| ○ Liver / Detoxification | 3.0 | LiverTox category D (rare cause of clinically apparent liver injury). Two DILI case reports confounded by anabolic steroid co-use. Standardized extract RCTs show no clinically significant LFT changes. |
| ○ Chronic Pain Management | 3.0 | Cortisol/HPA modulation is chronic-pain-adjacent. No direct pain RCTs. |
| ○ Social Bonding / Empathy | 3.0 | Mood and T changes may affect social confidence; no direct data. |
Frequently Asked Questions
What is Tongkat Ali and how does it work?
Tongkat Ali is a Malaysian root (Eurycoma longifolia) used traditionally for energy, libido, and post-partum recovery. Standardized hot-water extracts (Physta, LJ100) concentrate quassinoids - primarily eurycomanone - that displace testosterone from sex-hormone-binding globulin (SHBG), raising free T without new synthesis. Eurycomanone also stimulates LH pulsatility, and glycosaponins dampen HPA-axis cortisol. Effects are largest in stressed or hypogonadal men and muted in healthy young eugonadal adults.
What is the best dose of Tongkat Ali?
The RCT-validated dose is 200 mg/day of standardized Physta or LJ100, single AM dose. This is what Tambi 2012 used in hypogonadal men and what Talbott 2013 used for cortisol modulation. The Huberman-era community dose of 400 mg/day is an upward extrapolation without direct RCT support. 600 mg/day is the community ceiling. Never dose in the evening - insomnia is consistent. Do not stack multiple Tongkat products unless you have summed eurycomanone content.
Does Tongkat Ali actually increase testosterone?
Yes, in the right population. The Leitão 2021 meta-analysis of 11 RCTs (n=530) found a statistically significant total T increase with standardized extract versus placebo. The effect is largest in men with confirmed low baseline T: Tambi 2012 normalized serum T in 90.8% of hypogonadal men on 200 mg/day Physta for 1 month (mean T rose from 411 to 742 ng/dL). In healthy eugonadal young men the signal is noticeably weaker. It is a delta-to-baseline effect, not a flat population effect.
Is Tongkat Ali safe for the liver?
Standardized Physta and LJ100 RCTs up to 12 weeks report no clinically significant liver enzyme changes. LiverTox classifies likelihood category D (rare cause of clinically apparent injury). Two published DILI case reports in bodybuilders are confounded by heavy anabolic steroid co-use. The EFSA 2021 opinion flagged in-vivo DNA damage in rat stomach/duodenum at 2,000 mg/kg bw (roughly 160–200× the clinical dose), which cannot be dismissed. Net: safe at clinical doses of verified extracts, with residual uncertainty at high chronic community doses.
How long does Tongkat Ali take to work?
Cortisol and mood endpoints shift inside 2–4 weeks (Talbott 2013). Total T normalization in hypogonadal men was documented at the 1-month mark in Tambi 2012. Libido and subjective energy are often reported within 1 week anecdotally. Effects wash out over 1–3 weeks after discontinuation - there is no permanent HPG recalibration. Plan for 4–12 week cycles, not lifelong supplementation.
Physta vs LJ100 vs standardized - which Tongkat Ali extract is best?
Physta (Biotropics Malaysia, MS 2409:2011 standardized to 0.8–1.5% eurycomanone, ≥22% protein, ≥30% polysaccharide, ≥40% glycosaponin) and LJ100 (HP Ingredients, 100:1 hot-water root extract) dominate the clinical literature - Tambi, Talbott, George, Henkel, and Ismail all used one of these. Both publish heavy-metal COAs and maintain supply-chain traceability. Bulk unverified Southeast Asian root powder is functionally a lottery ticket: a Malaysian market survey found 42% contained zero measurable eurycomanone and 26–36% exceeded the 0.5 ppm mercury limit (range 2.35–5.30 ppm). Only buy Physta or LJ100.
Can women take Tongkat Ali?
Most clinical trials excluded women. A small preliminary pilot in perimenopausal women (Tambi 2011, conference abstract only) suggested DHEA and free estradiol support, but no robust RCTs exist. The EFSA 2021 opinion explicitly excludes pregnant and lactating women due to positive in-vivo DNA damage signals in rat reproductive-relevant tissues. For non-pregnant women with measurable HPA dysregulation the risk/benefit is unquantified; this is not a validated female-hormone tool.
What's the difference between Tongkat Ali and Fadogia Agrestis?
Tongkat Ali has 11+ human RCTs, a meta-analysis, and centuries of traditional use; Fadogia Agrestis has zero human trials and its popularity rests on a single rat study. The Huberman-popularized T&T stack combines them, but the evidence bases are not remotely equivalent. Tongkat Ali is the serious half of that stack. Fadogia's safety profile in humans is genuinely unknown. If forced to pick one, pick Tongkat Ali (Physta or LJ100) at 200–400 mg/day.
How This Score Could Change
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
| Scenario | Dimension shifts | New score |
|---|---|---|
| Large independent (non-industry) Western RCT replicates T and stress findings in n>500 | Evidence 3.0→3.8, Bioindiv 2.8→3.2 | 6.9 / 10 (👍 Worth trying) |
| Rigorous long-duration safety trial (12+ months) confirms no DILI or clastogenicity at clinical doses | Safety 2.2→1.5, Side effects 2.5→2.0 | 7.0 / 10 (💪 Strong recommend) |
| Human confirmatory study validates the EFSA in-vivo DNA-damage signal at near-clinical doses | Safety 2.2→3.5 | 6.0 / 10 (👍 Worth trying) |
| Independent bioequivalence trial shows generic eurycomanone matches Physta, widening the accessible channel | Evidence 3.0→3.3, Cost 1.8→1.4 | 6.8 / 10 (👍 Worth trying) |
| Well-powered RCT in healthy eugonadal men under 30 shows null effect | Efficacy 3.0→2.5, Bioindiv 2.8→2.3 | 6.3 / 10 (👍 Worth trying) |
| Huberman-era community dose (400–600 mg) linked to new case series of hormonal or hepatic AEs | Safety 2.2→3.0, Side effects 2.5→3.2 | 6.1 / 10 (👍 Worth trying) |
| Well-designed female RCT demonstrates peri/post-menopausal libido and mood benefit | Breadth 3.0→3.5, Bioindiv 2.8→3.3 | 6.9 / 10 (👍 Worth trying) |
Key Evidence Sources
- Leitão AE, et al. 2021. A 6-month, double-blind, placebo-controlled, randomized trial to evaluate the effect of Eurycoma longifolia (Tongkat Ali) and concurrent training on erectile function and testosterone levels - systematic review + meta-analysis. Phytother Res.. Meta-analysis of 11 RCTs (n=530). Statistically significant total T increase; effect larger in hypogonadal men; heterogeneity driven by population and extract type.
- Tambi MI, Imran MK, Henkel RR. 2012. Standardised water-soluble extract of Eurycoma longifolia, Tongkat ali, as testosterone booster for managing men with late-onset hypogonadism? Andrologia 44 Suppl 1:226-230.. 200 mg/day Physta, 1 month, n=76 hypogonadal aging men. 90.8% normalized into reference range. Mean T 411→742 ng/dL.
- Talbott SM, et al. 2013. Effect of Tongkat Ali on stress hormones and psychological mood state in moderately stressed subjects. J Int Soc Sports Nutr 10:28.. 200 mg/day Physta, 4 weeks, n=63. Salivary cortisol −16%, T:C ratio +37%, POMS tension/anger/confusion improvements.
- George A, Henkel R. 2014. Phytoandrogenic properties of Eurycoma longifolia as natural alternative to testosterone replacement therapy. Andrologia 46(7):708-721.. Physta RCT on vitality, libido, and sexual performance in men. Free T +16.4% vs control.
- Henkel RR, et al. 2014. Tongkat Ali as a potential herbal supplement for physically active male and female seniors - a pilot study. Phytother Res 28(4):544-550.. 200 mg/day, 5 weeks. Significant improvement in testosterone, muscle force, and total lean body mass in seniors.
- Hamzah S, Yusof A. 2003. The ergogenic effects of Eurycoma longifolia Jack: a pilot study. Br J Sports Med 37:464-470.. 5-week RCT, 100 mg/day water extract, n=14 physically active men. +1.8 kg lean mass, +5.6% bench, +6.1% leg press vs control.
- Ismail SB, et al. 2012. Randomized clinical trial on the use of Physta freeze-dried water extract of Eurycoma longifolia for the improvement of quality of life and sexual well-being in men. Evid Based Complement Alternat Med 2012:429268.. 12-week RCT, 300 mg/day Physta. SF-36 physical functioning, libido, and erectile function improvements.
- EFSA Panel on Nutrition, Novel Foods and Food Allergens. 2021. Safety of a water extract of Eurycoma longifolia (Tongkat Ali) as a novel food. EFSA Journal 19(12):6937.. Novel food opinion on Physta: safety not established under any condition of use. Positive in-vitro clastogenicity and in-vivo DNA damage in rat stomach/duodenum at 2,000 mg/kg bw. Pregnant/lactating explicitly excluded.
- LiverTox: Eurycoma longifolia (Tongkat Ali). National Institute of Diabetes and Digestive and Kidney Diseases.. Likelihood category D (rare cause of clinically apparent liver injury). Two DILI case reports in bodybuilders with heavy anabolic steroid co-use as confounder.
- Thu HE, et al. 2017. Eurycoma longifolia as a potential adoptogen of male sexual health: a systematic review on clinical studies. Chin J Nat Med 15(1):71-80.. Systematic review supporting stress, fatigue, and mood benefit signals across multiple cohorts.
- Ang HH, Lee KL. 2002. Contamination of mercury in Tongkat Ali hitam herbal preparations. Food Chem Toxicol 40(8):1245-1250.. Malaysian market survey documenting heavy metal contamination. Subsequent work: 26–36% of samples exceed 0.5 ppm mercury (range 2.35–5.30 ppm). Informs the supply-chain warning.
- Biotropics Malaysia Physta monograph. MS 2409:2011 Malaysian Standard for Eurycoma longifolia root extract.. Standardized spec: 0.8–1.5% eurycomanone, ≥22% protein, ≥30% polysaccharide, ≥40% glycosaponin. Third-party COA available.
- Low BS, Das PK, Chan KL. 2013. Standardized quassinoid-rich Eurycoma longifolia extract improved spermatogenesis and fertility in male rats via the hypothalamic-pituitary-gonadal axis. J Ethnopharmacol 145(3):706-714.. Mechanistic preclinical data supporting LH/HPG axis upregulation in rats.
- Tambi MI. 2005. Eurycoma longifolia Jack: a potent adaptogen in the form of water-soluble extract (LJ100) in the management of male ageing. Proceedings of the 11th Biennial Meeting of The International Society for the Study of the Aging Male.. Early clinical observations supporting the aging-male responder phenotype.
Other interventions for Stress / Resilience
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. 5.0 is neutral (benefits and risks balance). Above 5 = benefits outweigh risks; below 5 = risks outweigh benefits.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 1.830 − 0.960 = 0.870
EV ranges from −5 to +5. Adding 7 shifts to 2–12, dividing by 12 normalizes to 0–1, then ×10 gives the 0–10 score.
Score = ((0.870 + 7) / 12) × 10 = 6.6 / 10
Further learning
Biohacking Testosterone Protocol: Powerful & Natural Optimization
Testosterone is an incredibly misunderstood yet vital hormone for both men and women. Contrary to popular belief, it's low testosterone that's especially dangerous. This…
Superior Herbs That Raise Testosterone, Balance Hormones, & Boost Performance (He Shou Wu, Pine Pollen, Blue Vervain, Shilajit & More)
What separates an average supplement routine from a superior one? Drawing from both ancient herbalism & modern performance science, Logan Christopher from Lost Empire…
